[1] EDWARDS I R, ARONSON J K. Adverse drug reactions: definitions, diagnosis, and management[J]. Lancet, 2000,356(9237): 1255-1259.
[2] PIRMOHAMED M, BRECKENRIDGE A M, KITTERINGHAM N R, et al. Adverse drug reactions[J]. BMJ, 1998,316(7140): 1295-1298.
[3] CAMERON H A, RAMSAY L E. The lupus syndrome induced by hydralazine: a common complication with low dose treatment[J]. Br Med J (Clin Res Ed), 1984,289(6442): 410-412.
[4] MALLAL S, PHILLIPS E, CAROSI G, et al. HLA-B*5701 screening for hypersensitivity to abacavir[J]. N Engl J Med, 2008,358(6): 568-579.
[5] SAAG M, BALU R, PHILLIPS E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients[J]. Clin Infect Dis, 2008,46(7): 1111-1118.
[6] PULLEN H, WRIGHT N, MURDOCH J M. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis[J]. Lancet, 1967,2(7527): 1176-1178.
[7] LAZAROU J, POMERANZ B H, COREY P N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies[J]. JAMA, 1998,279(15): 1200-1205.
[8] CHYKA P A. How many deaths occur annually from adverse drug reactions in the United States?[J]. Am J Med, 2000,109(2): 122-130.
[9] BATES D W, CULLEN D J, LAIRD N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group[J]. JAMA, 1995,274(1): 29-34.
[10] BATES D W, SPELL N, CULLEN D J, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group[J]. JAMA, 1997,277(4): 307-311.
[11] National annual report on adverse drug reaction monitoring in 2021.[EB/OL]. (2021-03-26)[06]. http://www.cdr-adr.org.cn/tzgg_home/202103/t20210326_48414.html.
[12] JEFFERYS D B, LEAKEY D, LEWIS J A, et al. New active substances authorized in the United Kingdom between 1972 and 1994[J]. Br J Clin Pharmacol, 1998,45(2): 151-156.
[13] ZHANG X, NIU R, FENG B, et al. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study[J]. Expert Opin Drug Saf, 2019,18(1): 59-68.
[14] GUO X J, YE X F, WANG X X, et al. Reporting patterns of adverse drug reactions over recent years in China: analysis from publications[J]. Expert Opin Drug Saf, 2015,14(2): 191-198.
[15] Adverse Drug Reaction Reporting and Monitoring Management Measures(Ministry of Health Order No. 81)[EB/OL]. [2021/5/25]. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm.
[16] ZHANG L, WONG L Y, HE Y, et al. Pharmacovigilance in China: current situation, successes and challenges[J]. Drug Saf, 2014,37(10): 765-770.
[17] WANG J G, WANG N. The Present Situation and Management Measures of Adverse Drug Reactions in China[M]//Hee T, Liu J. Advances in Social Science Education and Humanities Research. PARIS: ATLANTIS PRESS, 2016:311-314.
[18] JIANG C, SHEN J, SHOU D, et al. Identification of high-risk patients for ADR induced by traditional Chinese medicine injection: a nested case-control study[J]. Sci Rep, 2019,9(1): 16721.
[19] SANDOVAL T, MARTINEZ M, MIRANDA F, et al. Incident adverse drug reactions and their effect on the length of hospital stay in older inpatients[J]. Int J Clin Pharm, 2020.
[20] MENDES D, OLIVEIRA A R, ALVES C, et al. Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis[J]. Expert Opin Drug Saf, 2020,19(6): 763-769.
[21] MODI A, DESAI M, SHAH S, et al. Analysis of Cutaneous Adverse Drug Reactions Reported at the Regional ADR Monitoring Center[J]. Indian J Dermatol, 2019,64(3): 250.
[22] WESTER K, JONSSON A K, SPIGSET O, et al. Incidence of fatal adverse drug reactions: a population based study[J]. Br J Clin Pharmacol, 2008,65(4): 573-579.
[23] GUNER M D, EKMEKCI P E. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates[J]. J Drug Assess, 2019,8(1): 13-20.
[24] CHABANON A L, WAGUE S, MOUREAU A, et al. Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season[J]. BMC Public Health, 2021,21(1): 358.
[25] DEB T, GHOSH A, DALAI C K, et al. Impact of Climatic Variations on Drug-induced Skin Reactions in Two Different Regions of India[J]. Curr Drug Saf, 2021,16(1): 90-96.
[26] LIU Y, WANG R, HUANG R, et al. Influencing factors and their relationships of risk perception and decision-making behaviour of polypharmacy in patients with chronic diseases: a qualitative descriptive study[J]. BMJ Open, 2021,11(4): e43557.
[27] ZHANG W, ZHANG J, MA R, et al. Patient expectations and awareness of information regarding adverse reactions in drug labelling in China[J]. Int J Clin Pharm, 2021,43(1): 174-180.
[28] LI H, DENG J, DENG L, et al. Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China[J]. Pharmacoepidemiol Drug Saf, 2019,28(7): 1002-1013.
[29] WANG J G, WANG N. Supervisory Control of Adverse Reaction of Traditional Chinese Medicine Injection[M]//Xiao X, Xue H, Khan S. Advances in Social Science Education and Humanities Research. PARIS: ATLANTIS PRESS, 2017:167-169.
[30] HU Q, DENG S, LING L, et al. Influencing Factors for Adverse Drug Reactions of Chinese Herbal Formula Aidi Injection[J]. JOURNAL OF MEDICAL IMAGING AND HEALTH INFORMATICS, 2017,7(6): 1226-1232.
[31] BIGI C, BOCCI G. The key role of clinical and community health nurses in pharmacovigilance[J]. Eur J Clin Pharmacol, 2017,73(11): 1379-1387.
[32] OGAR C K, ABIOLA A, YUAH D, et al. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016[J]. Pharmaceut Med, 2019,33(2): 145-157.
[33] OREAGBA I A, OSHIKOYA K A, OGAR C, et al. Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016[J]. Pharmacol Res Perspect, 2017,5(2): e297.
[34] VARALLO F R, PLANETA C S, MASTROIANNI P C. Effectiveness of pharmacovigilance: multifaceted educational intervention related to the knowledge, skills and attitudes of multidisciplinary hospital staff[J]. Clinics (Sao Paulo), 2017,72(1): 51-57.
[35] FARIA E, RODRIGUES-CERNADAS J, GASPAR A, et al. Drug-induced anaphylaxis survey in Portuguese Allergy Departments[J]. J Investig Allergol Clin Immunol, 2014,24(1): 40-48.
[36] GUNER M D, EKMEKCI P E. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates[J]. J Drug Assess, 2019,8(1): 13-20.